ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for head and neck cancer patients who Can't take standard chemo
Disease control OngoingThis early-stage trial tests a drug called peposertib combined with radiation therapy for people with advanced head and neck cancer who cannot take the standard chemotherapy drug cisplatin. The goal is to find the safest dose of peposertib and see if the combination helps control…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:02 UTC
-
Cancer vaccine plus immunotherapy shows promise in advanced lung and Head/Neck tumors
Disease control OngoingThis study tests a combination of the CIMAvax vaccine (which targets a protein that helps tumors grow) and nivolumab (an immunotherapy that boosts the immune system) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best …
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Head and neck cancer trial tests easier chemo schedule
Disease control TerminatedThis study compares two different schedules of the chemotherapy drug cisplatin given alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose every week. The goal is to see which schedule causes f…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 11, 2026 20:47 UTC